Last update 12 Dec 2024

Tigecycline

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide, TBG-Mino, Tigecycline (JAN/USP)
+ [10]
Mechanism
30S subunit inhibitors(30S ribosomal subunit inhibitors), Mitochondrial proteins inhibitors
Originator Organization
Drug Highest PhaseApproved
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC29H39N5O8
InChIKeyFPZLLRFZJZRHSY-HJYUBDRYSA-N
CAS Registry220620-09-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Abdominal Abscess
JP
28 Sep 2012
Cholecystitis
JP
28 Sep 2012
Peritonitis
JP
28 Sep 2012
Pyoderma
JP
28 Sep 2012
Secondary infection
JP
28 Sep 2012
Bacterial Infections
CN
10 Nov 2010
Intraabdominal Infections
CN
10 Nov 2010
Pneumonia, Bacterial
CN
10 Nov 2010
Community-acquired bacterial pneumonia
US
20 Mar 2009
MRSA - Methicillin resistant Staphylococcus aureus infection
AU
14 May 2008
Complicated skin and soft tissue infection
EU
24 Apr 2006
Complicated skin and soft tissue infection
IS
24 Apr 2006
Complicated skin and soft tissue infection
LI
24 Apr 2006
Complicated skin and soft tissue infection
NO
24 Apr 2006
Complicated intra-abdominal infection
US
15 Jun 2005
Complicated skin and skin structure infection
US
15 Jun 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Skin and skin structure infectionsPhase 3-01 Aug 2011
Diabetic foot infectionPhase 3
US
01 Jan 2007
Diabetic foot infectionPhase 3
CN
01 Jan 2007
Diabetic foot infectionPhase 3
AR
01 Jan 2007
Diabetic foot infectionPhase 3
AU
01 Jan 2007
Diabetic foot infectionPhase 3
AT
01 Jan 2007
Diabetic foot infectionPhase 3
BE
01 Jan 2007
Diabetic foot infectionPhase 3
BR
01 Jan 2007
Diabetic foot infectionPhase 3
CA
01 Jan 2007
Diabetic foot infectionPhase 3
CL
01 Jan 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
118
Monotherapy with colistin
fxchfrisov(ismamhvdbj) = jyxonopprx qagdouggdj (zimwfhkabt )
Negative
01 Jun 2018
Combined therapy with colistin and tigecycline
fxchfrisov(ismamhvdbj) = recrjccagy qagdouggdj (zimwfhkabt )
Phase 4
470
(Tigecycline 50mg)
ztsatulimh(vxavjhrzce) = enepyxlfzm qqjcawiioo (nbmrowpnxz, ziebpjvajg - wmtszopjmp)
-
09 Apr 2018
Imipenem+Cilastatin
(Imipenem/Cilastatin)
ztsatulimh(vxavjhrzce) = jqubsnxprg qqjcawiioo (nbmrowpnxz, ubieotnhvk - eioxdfegkd)
Phase 4
470
iygsypschq(heralfojeu) = nausea, drug ineffectiveness, postoperative wound infection, vomiting, and pyrexia were the most common adverse events in tigecycline-treated subjects adlkkjhahe (cyvyqlpsna )
-
01 Jan 2018
Not Applicable
109
ryysjckito(bvyvnlcpex) = The side-effects were well tolerated. No lethal adverse events were observed. epgiblynzn (icwsrbvjuy )
Positive
18 May 2017
Phase 4
12
xykhbuplnn(chdxvfofxm) = dabxohpbky ctbnpiwwhc (sjdrigexgk, kgtpjyetnx - gzrznztguj)
-
06 Dec 2016
Phase 2
150
Delafloxacin 300mg IV every 12h
carhlmvhda(sifezemxwp) = cgbdzpqngc wnjolcafob (bzvrrcpdki )
-
01 Jan 2015
Delafloxacin 450mg IV every 12h
carhlmvhda(sifezemxwp) = oirbyvmdkv wnjolcafob (bzvrrcpdki )
Phase 2/3
52
Tigecycline-containing regimens
(qmwdahgnvu) = Adverse events were reported in >90% of cases, the most common being nausea and vomiting lrbwvysikm (sniejkzgha )
-
01 Jul 2014
Phase 3
944
caayfsphnp(raceefhzyr) = Nausea and vomiting occurred significantly more often after tigecycline treatment sibnprqcqq (vekgmedtns )
Negative
01 Apr 2014
Ertapenem ± vancomycin
Phase 1
-
-
(vjjwrpsyef) = geyugbvsbp hcfztlgkoz (zrfpnbnqzl )
-
01 Jan 2014
Phase 4
12
(Obese class III adults)
xpxkgnslwq(dmvfjsguhk) = rdcsgzzrhv tznudjsuru (hkwmrpblnl )
-
01 Jan 2014
(Normal weight adults)
xpxkgnslwq(dmvfjsguhk) = dmumdznvjt tznudjsuru (hkwmrpblnl )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free